• Endoscopic Sleeve Gastroplasty for Treatment of Obesity

  NCT02231970

  Unknown statusInterventionalNot ApplicableUpdated Sep 5, 2014
• Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty

  NCT07576777

  Not yet recruitingInterventionalNot ApplicableUpdated May 8, 2026
• Endoscopic Sleeve Gastroplasty

  NCT02948621

  CompletedObservationalUpdated Jan 8, 2024
• Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity

  NCT06339320

  RecruitingInterventionalNot ApplicableUpdated Apr 1, 2024
• Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial

  NCT04200144

  Unknown statusInterventionalNot ApplicableUpdated Feb 28, 2024
• Identification of Factors Predictive of the Efficacy of Endoscopic Endoscopic Sleeve Gastroplasty

  NCT06153056

  RecruitingObservationalUpdated Jan 21, 2026

ClinicalTrials.gov ID

NCT07449520

Lead Sponsor

IHU StrasbourgOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

300Estimated

Last Update Posted

Mar 4, 2026Actual

Start Date

Mar 2026Estimated

Primary Completion Date

Mar 2030Estimated

Completion Date

Mar 2030Estimated

Official Title

Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity

Brief Summary

EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions

The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.

Detailed Description

Obesity, particularly morbid obesity, is a major public health issue in France. According to the latest data from the ObÉpi-Roche 2020 survey, more than 17% of French adults are obese. Obesity is a well-established risk factor for many chronic diseases such as type 2 diabetes, cardiovascular disease, high blood pressure (HBP), musculoskeletal disorders, certain cancers, and non-alcoholic steatohepatitis (NASH). It is associated with a significant reduction in life expectancy and represents a direct cost estimated at more than €5 billion per year for the French healthcare system.

While bariatric surgery (particularly sleeve gastrectomy and gastric bypass) remains the gold standard treatment for severe obesity, it is invasive, costly, and only offered to a minority of patients (less than 10% of eligible patients). In addition, certain medical contraindications, refusal of surgery, and waiting times limit access to this treatment.

Endoscopic sleeve gastroplasty ("Endosleeve"). Endoscopic sleeve gastroplasty (ESG) is an innovative, non-surgical, natural procedure that reduces stomach volume without resection or anastomosis. It has shown promising results in terms of weight loss, metabolic improvement, and safety, while being reversible and reproducible. The MERIT randomized controlled trial in USA (JAMA, 2022) demonstrated an average weight loss of 13.6% of total body weight at 12 months (vs. 0.8% in the control group), as well as a significant improvement in comorbidities such as type 2 diabetes and hypertension.

Hypothesis and objective of the study The hypothesis of this study is that ESG, when performed under routine care conditions in the United States, leads to significant and sustainable weight loss, associated with an improvement in comorbidities, with a favorable safety profile. The main objective of this project is therefore to evaluate, on a national scale, the clinical efficacy, safety, and procedural variability of ESG through a multicenter real-world cohort.

To date, no large-scale French study has analyzed the results of ESG in real-world settings. This hinders its integration into national healthcare pathways, its reimbursement by the French national health insurance system, and its wider adoption by the medical community. The question raised-the rigorous evaluation of ESG in the French context-therefore remains unanswered.

This project aims to generate robust data representative of the national clinical reality in order to support the supervised development of ESG. Expected outcomes include the publication of scientific articles in peer-reviewed journals, the presentation of results at international conferences, contributions to health technology assessment work, and the establishment of a national registry of endoscopic gastroplasty. This work could represent a major advance in the therapeutic arsenal for obesity, supporting the integration of ESG as a recognized, validated, and reimbursed option in French healthcare pathways.

• Obesity

• Endoscopic sleeve gastroplasty

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patients aged 18 to 75 years.
• Patients with a Body Mass Index (BMI) ≥ 30 kg/m².
• Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).
• Patients not eligible for bariatric surgery or does not wish to undergo it.
• Patients who can undergo general anesthesia.
• Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.
• Patients who are able to fully understand the study and are willing to give their consent to participate in the study.
• Patients affiliated with the French social security system.

Exclusion Criteria:

• Patients with contraindications to endoscopic gastroplasty
• Patients with active peptic ulcer disease or significant gastroparesis
• Patients with a history of bariatric, gastric, or esophageal surgery.
• Patients who have started medication in the last 3 months that is known to cause weight gain.
• Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.
• Patients with unstable and precarious health, as determined and assessed by the investigator.
• Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.
• Patients who are currently excluded (as determined by a previous or ongoing study).
• Patients under judicial protection.
• Patients under guardianship, conservatorship or subject to any form of protective supervision

Observational Model

Case-Only

Time Perspective

Prospective

Lead Sponsor

IHU StrasbourgOTHER

Collaborators

SOFF.COMMUNKNOWN

Boston Scientific International S.A.UNKNOWN

docteur.mercoli@gmail.com0033 3 81 41 81 41

fabien.stenard@cliniquedescedres.com0033 4 56 58 14 90

robert.caiazzo@univ-lille2.fr0033 3 20 44 42 73

docteur.m.silvestri@gmail.com0033 4 67 06 70 00

PBLANC@mutualite-loire.com0033 4 77 81 82 88

thibautcoste@gmail.com0033 4 67 18 88 20

zulemacu@yahoo.com0033 5 90 25 95 65